Navigation Links
DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
Date:10/26/2009

CUPERTINO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, October 29, 2009 at 4:30 pm Eastern Time (1:30 pm Pacific Time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR®, TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for
'/>"/>

SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
4. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
5. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
6. Select Medical Holdings Corporation Announces Exercise of Underwriters Option to Purchase Additional Shares
7. Digirad Corporation to Present at BIOCOM 4th Annual Investor Conference
8. Mirixa Corporation Announces MirixaEdge(SM)
9. WebMD and HLTH Corporation to Webcast Annual Meetings of Stockholders
10. Baxa Corporation Signs Exclusive Distribution Agreement With Leading Pharmaceutical Corporation in Peoples Republic of China
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
(Date:1/15/2014)... 15, 2014 Tegra Medical is very pleased to announce ... its new Chief Executive Officer.  Mark was promoted from his ... overseen the company,s four facilities in Massachusetts ... King joined Tegra Medical in 2012 with 20+ years of ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... , HOFFMAN ESTATES, Ill. , Jan. 28 ... and Drug Administration (FDA) has given 510(k) marketing clearance to ... System. , The DYNA-LINK system features a next-generation stand-alone device ... system is a thoracolumbar plating system that features multiple types ...
... , INDIANAPOLIS , Jan. 28 , Double-digit revenue ... Q4 gross margin Company delivers Q4 earnings per share of ... EPS rises to $3.94 (reported) or $4.42 (pro forma non-GAAP) ... 2010 EPS guidance range reconfirmed at $4.65 to $4.85 ...
Cached Medicine Technology:Lilly Reports Fourth-Quarter and Full-Year 2009 Results 2Lilly Reports Fourth-Quarter and Full-Year 2009 Results 3Lilly Reports Fourth-Quarter and Full-Year 2009 Results 4Lilly Reports Fourth-Quarter and Full-Year 2009 Results 5Lilly Reports Fourth-Quarter and Full-Year 2009 Results 6Lilly Reports Fourth-Quarter and Full-Year 2009 Results 7Lilly Reports Fourth-Quarter and Full-Year 2009 Results 8Lilly Reports Fourth-Quarter and Full-Year 2009 Results 9Lilly Reports Fourth-Quarter and Full-Year 2009 Results 10Lilly Reports Fourth-Quarter and Full-Year 2009 Results 11Lilly Reports Fourth-Quarter and Full-Year 2009 Results 12Lilly Reports Fourth-Quarter and Full-Year 2009 Results 13Lilly Reports Fourth-Quarter and Full-Year 2009 Results 14Lilly Reports Fourth-Quarter and Full-Year 2009 Results 15Lilly Reports Fourth-Quarter and Full-Year 2009 Results 16Lilly Reports Fourth-Quarter and Full-Year 2009 Results 17Lilly Reports Fourth-Quarter and Full-Year 2009 Results 18Lilly Reports Fourth-Quarter and Full-Year 2009 Results 19Lilly Reports Fourth-Quarter and Full-Year 2009 Results 20Lilly Reports Fourth-Quarter and Full-Year 2009 Results 21Lilly Reports Fourth-Quarter and Full-Year 2009 Results 22Lilly Reports Fourth-Quarter and Full-Year 2009 Results 23Lilly Reports Fourth-Quarter and Full-Year 2009 Results 24Lilly Reports Fourth-Quarter and Full-Year 2009 Results 25Lilly Reports Fourth-Quarter and Full-Year 2009 Results 26Lilly Reports Fourth-Quarter and Full-Year 2009 Results 27Lilly Reports Fourth-Quarter and Full-Year 2009 Results 28
(Date:7/9/2014)... at the Perelman School of Medicine at the University ... Institute have received an $8 million grant from the ... photodynamic light therapy (PDT) in patients with malignant pleural ... often manifests itself in the lining of the lungs ... The grant will fund a clinical trial and additional ...
(Date:7/9/2014)... A network of signals active in almost all types ... into overdrive, and may help fuel a tumour,s uncontrolled ... of Cancer Research, London, identified a molecular trigger responsible ... the cellular factory that makes the building blocks ... in the TOR signalling pathway, called SREBP, controls the ...
(Date:7/9/2014)... researchers have uncovered mutations in a cell-signaling pathway that ... may expand treatments for patients because drugs targeting some ... in clinical trials. , Reporting July 9 in ... including researchers at Washington University School of Medicine in ... tumors from 230 patients with lung adenocarcinoma. , "This ...
(Date:7/9/2014)... Cancer Center paint a relatively optimistic picture of women,s ... have spread to the chest wall or skin, but ... skin, regardless of size and whether they have involved ... and called "locally advanced" tumors, suggesting that they are ... survival. Locally advanced breast cancers of this and other ...
(Date:7/9/2014)... used in policing injection drug users in Russia ... , A study, conducted by researchers from ... in collaboration with St. Petersburg Pavlov State University, ... on the health outcomes of a cohort of ... , Those who were arrested by police were ...
Breaking Medicine News(10 mins):Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2
... rates began to rise again around 2000, researchers have been ... especially in the homosexual community. The rising numbers are a ... to increased awareness of the virus. A new study in ... each year in the last decade saw a startling increase ...
... clinicians with expertise in polypharmacy, caregiving and more ... a free conference examining Alzheimer,s disease. The ... join with the Greater Kentucky and Southern Indiana ... Journey: Alzheimer,s Disease and Caregiving" from 9 a.m. ...
... Steven Reinberg HealthDay Reporter , WEDNESDAY, Aug. 24 ... they have found changes in the chemistry of the brains ... at future risk for Alzheimer,s disease and other dementias. ... the disease, experts say finding ways to identify those at ...
... Reporter , WEDNESDAY, Aug. 24 (HealthDay News) -- Since 2010, ... available at all has risen dramatically, according to the U.S. ... drugs given by injection and used in hospitals to treat ... are putting patients at risk and compromising their care, experts ...
... The Food and Drug Administration has cleared a new ... of thousands of AIDS patients stricken with cryptococcosis, a fungal ... Kozel, professor of microbiology of the University of Nevada School ... (Immuno-Mycologics) of Oklahoma. The new, rapid blood test known ...
... of HIV have increased in Pakistan,s general population, ... to women and their children, according to an ... Florida scientist. The researchers raise concern that ... may serve as indication that the virus may ...
Cached Medicine News:Health News:Why HIV infection rates are on the rise 2Health News:UofL experts featured at free Alzheimer's disease conference Sept. 17 2Health News:Sophisticated Scan May Spot Seeds of Alzheimer's Risk 2Health News:Sophisticated Scan May Spot Seeds of Alzheimer's Risk 3Health News:Cancer Drug Shortages Getting Worse, FDA Says 2Health News:Cancer Drug Shortages Getting Worse, FDA Says 3Health News:FDA clears new IMMY and University of Nevada, Reno life-saving blood test 2Health News:Study of HIV increase in Pakistan could benefit other research 2
... ExTOL systems feature your choice of ... electrocardiographs, an easy-to-operate monitor and the ... exercise stress testing systems also feature ... point, pre-programmed or custom protocols, and ...
... w/ Remote/Controller. Includes Full Range ... Children. Multiple 20/20 slides. Polarized ... allows you to customize your slide choices. ... with Long Life. Variety of mounting options. ...
... Ultimate in Stability. ... stabilizer features superior arm ... in the clamp/turret mechanism. ... features the ultimate flexibility ...
... leader in beating heart bypass, comes the ... NS device is the first leap in ... of surgical revascularization.,The Starfish NS Heart Positioner ... Small Thoracotomy (MVST) procedure without CPB and ...
Medicine Products: